Navamedic reached another all time high

Navamedic ASA, the Norwegian pharmaceutical products company, today announced its fourth quarter and 2011 full year results. Sales reached yet another all time high in the fourth quarter and profit margins improved significantly. Navamedic also made its debut in the generic pharmaceuticals market in the quarter.

"The combination of increasing sales and profitability in our traditional business area while we move into the new and exciting generics segment confirms that Navamedic's strategy is proving successful," said CEO Olof Milveden.

Navamedic sales in the fourth quarter were NOK 19.2 million, which is a 22 per cent growth over the previous year's fourth quarter. Sales were mainly attributable to the Vitaflo business area, however the new Generics business area posted sales for the first time with revenues of NOK 0.1 million.

While Vitaflo profitability continues to improve, Navamedic's group results are affected by costs related to the build-up of its new generics business. The Group's EBITDA came in at NOK 0.3 for the quarter, a significant improvement over the corresponding quarter last year.

Navamedic launched its two first generic drugs in the fourth quarter and is well underway towards building a position in this fast growing segment. The Company currently has 11 generic products filed for approval and expects to launch eight of these in the market during 2012. Generics developing costs and capitalised investments in the business area totalled NOK 5.7 million in the fourth quarter.

The Vitaflo business area, which is a distributor of health care products and patented drugs in the Nordic markets, experienced high sales growth also in the fourth quarter. Profitability continued to improve and the EBITDA margin reached 10 per cent in the fourth quarter.

For the full year, Navamedic's sales grew by almost 30 per cent and reached NOK 71.3 million. EBITDA after generics development costs came in at NOK -2.6 million, a significant improvement over the previous year's EBITDA of NOK -6.5 million.

Navamedic forecasts continued double digit sales growth and attractive margins in its Vitaflo business area. As generics products are rolled out during 2012, the Company expects profitability also in this area towards the end of the year.

Related news

Latest news

New contract: Windcat 41 - no 17 in the Servogear series

Servogear announces the signing of a new contract with Windcat Workboats BV for the delivery of Servogear Controllable Pitch Propellers (CPP)  for their new vessel Windcat 41. 

Seacat Enterprise to be launched January 12th

Seacat Services, is preparing to launch its first High Speed Utility Vessel (HSUV), Seacat Enterprise at January 12th.

Norsafe Signs Contract with the Swedish Coast Guard (KBV)

On Wednesday 21st December, Norsafe signed yet another new contract with the Swedish Coast Guard (KBV) to deliver nine new Magnum 750 MKII boats.

A Unique Second-generation Tomograph is Developed

A new gamma-ray tomograph designed to image up to 4” diameter pipes, is developed by CMR Prototech for the Saskatchewan Research Council (SRC) in Canada.

Sohome launches a new website

Sohome has launched a new website that makes it easier to find key information. 

Sohome AS receives orders for Johan Sverdrup Project

Sohome AS is proud to be a sub-contractor to Intelecom AS for the Johan Sverdrup Project. 

New 55'' Ultra High Definition Chart and Planning table passes Type Approval testing

Most advanced maritime display system ever produced, the 55'' Ultra High Definition Chart & Planning table, enables Integrated Bridge System manufacturers to develop new multi-data solutions.

Norsafe's experience in the Polar Code Pays Off

In readiness for the introduction of the Polar code, Norsafe has become the first LSA supplier to have executed full scale tests and trials 

Øglænd System Group winner of Business of the Year Award

Øglænd System Group won the Business of the Year Award in the Stavanger-region 2016.